文献速递前列腺癌

KEYNOTE-921患者报告结局:帕博利珠单抗联合多西他赛与泼尼松治疗转移性去势抵抗性前列腺癌

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-05-13

KEYNOTE-921研究评估帕博利珠单抗联合多西他赛与泼尼松对比化疗在经新一代激素治疗后未化疗的mCRPC患者中的患者报告结局。PRO分析集共1028例,中位随访22.7个月,两组至疼痛进展中位时间分别为21.1个月与未达到(HR 1.05,95%CI 0.77-1.43)。各PRO终点自基线的变化在两组间相似且总体稳定,未见有意义的差异。

要点

  • 联合帕博利珠单抗未显著改善至疼痛进展时间(HR 1.05,95%CI 0.77-1.43)
  • 两组健康相关生活质量及疾病相关症状变化相似且总体稳定
  • 加用免疫检查点抑制剂对经NHA治疗的mCRPC患者HRQoL无正负影响

核心结论

  • 在经新一代激素治疗的mCRPC患者中,帕博利珠单抗联合化疗对比单纯化疗未观察到有意义的PRO差异。
  • 加用免疫检查点抑制剂未对健康相关生活质量产生正面或负面影响。

研究设计与样本

  • 3期KEYNOTE-921研究的PRO分析,患者按1:1随机接受帕博利珠单抗或安慰剂联合多西他赛与泼尼松。
  • PRO分析集共1028例,中位随访22.7个月(自基线至数据库截止2022年6月20日)。
  • 至疼痛进展为次要终点,采用简明疼痛评估量表简表测量;HRQoL为预设探索性终点。

主要发现

  • 至疼痛进展中位时间:帕博利珠单抗组21.1个月(95%CI 13.7-未达到),安慰剂组未达到(95%CI 13.8-未达到)。
  • 至疼痛进展风险比1.05(95%CI 0.77-1.43)。
  • 各PRO终点自基线的变化在两组间相似,并在研究期间总体保持稳定。

关键数值与推荐

  • PRO分析集1028例;中位随访22.7个月。
  • 至疼痛进展中位时间:帕博利珠单抗组21.1个月(95%CI 13.7-NR),安慰剂组NR(95%CI 13.8-NR)。
  • 风险比1.05(95%CI 0.77-1.43)。

临床怎么用

  • 对于经NHA治疗的mCRPC患者,在化疗基础上加用帕博利珠单抗不改善也不损害生活质量。
  • 临床决策可参考该结果,PRO无显著差异不作为联合治疗的获益依据。

局限性

  • 缺乏检测组间PRO差异的正式假设检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In the phase 3 KEYNOTE-921 study, the combination of pembrolizumab with docetaxel did not improve efficacy outcomes significantly in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) after next-generation hormonal agents (NHAs). This analysis of KEYNOTE-921 assessed patient-reported outcomes (PROs) associated with pembrolizumab plus chemotherapy versus chemotherapy alone. METHODS: Eligible patients were assigned randomly in a 1:1 ratio to receive pembrolizumab or placebo, both with docetaxel and prednisone. The time to pain progression measured by the Brief Pain Inventory-Short Form was a secondary end point. Health-related quality of life (HRQoL) scores, including disease-related symptoms, assessed by the Functional Assessment of Cancer Therapy-Prostate and EuroQol five-dimension five-level were prespecified exploratory end points. KEY FINDINGS AND LIMITATIONS: The PRO analysis set comprised 1028 patients; the median follow-up was 22.7 mo from baseline until database cutoff (June 20, 2022). The median time to pain progression was 21.1 mo (95% confidence interval [CI] 13.7 to not reached [NR]) and NR (95% CI 13.8-NR) in the pembrolizumab and placebo arms, respectively (hazard ratio 1.05; 95% CI 0.77-1.43). Changes from baseline in PRO end points were similar between treatment arms and remained generally stable throughout the study. Limitations include a lack of formal hypothesis testing to detect between-arm differences in PROs. CONCLUSIONS AND CLINICAL IMPLICATIONS: No meaningful differences in PROs were observed in patients with mCRPC treated with pembrolizumab plus chemotherapy versus chemotherapy alone. These findings indicate that adding an immune checkpoint inhibitor to chemotherapy does not positively or negatively impact HRQol in patients with mCRPC previously treated with NHAs.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsubara N, Petrylak D, Ratta R, et al. Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40368743. doi:10.1016/j.euo.2025.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。